1. Volume 15, Issue 10, Pages 1109-1118 (September 2014)
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial 
J Athene Lane, PhD, Prof Jenny L Donovan, PhD, Michael Davis, MSc, Eleanor Walsh, MSc, Daniel Dedman, MSc, Liz Down, BSc, Emma L Turner, PhD, Prof Malcolm D Mason, FRCP, Chris Metcalfe, PhD, Prof Tim J Peters, PhD, Richard M Martin, PhD, Prof David E Neal, FMedSci, Prof Freddie C Hamdy, FMedSci 
The Lancet Oncology 
Volume 15, Issue 10, Pages (September 2014)
DOI: /S (14)
Copyright © 2014 Lane et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
ProtecT and CAP trial recruitment phases and endpoint assessment
CAP=Cluster randomised triAl of PSA testing for Prostate cancer. ProtecT=Prostate testing for cancer and Treatment. NHS=National Health Service.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Lane et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2
Flow diagram of the diagnostic phase of the main ProtecT trial
Results are from one round of PSA testing. ASAP=atypical small acinar proliferation. PIN=prostatic intraepithelial neoplasia. PSA=prostate-specific antigen.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Lane et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3 Flow diagram of the randomisation phase of the ProtecT trial
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Lane et al. Open Access article distributed under the terms of CC BY Terms and Conditions